Dr. Lal Path Labs growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.2%+10.5%+10.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+12.5%+14.1%+24.4%
+12.1%+18.9%+37.1%
+3.6%+35.9%+50.3%
−48.3%+35.8%+49.4%
+15.8%+10.6%+3.0%
+15.2%+17.0%+10.9%
+11.8%+6.2%+17.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health
₹ CrorePeersMETROPOLISVIJAYATHYROCARENATCOPHARMNEULANDLABNHCOHANCESAILIFEMcap ₹32,040 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.4+10.5+12.2—
EBITDA Growth—+24.4+14.1+12.5—
EBIT Growth—+37.1+18.9+12.1—
Net Income Growth—+50.3+35.9+3.6—
EPS Growth—+49.4+35.8-48.3—
Total Assets Growth—+3.0+10.6+15.8—
Total Equity Growth—+10.9+17.0+15.2—
Cash from Operations Growth—+17.4+6.2+11.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.